Paul Rosie is an associate in the firm’s Business Law Department and a member of its Technology Companies and Life Sciences group. His practice focuses on general corporate representation, venture capital financings, mergers and acquisitions, public offerings and SEC compliance. Mr. Rosie counsels emerging growth companies at all stages of maturity, including formation, initial funding, expansion and exit. He also represents venture capital funds and investment banks focusing on technology and life science companies. Mr. Rosie originally joined Goodwin in 2015.

Areas of Practice
Domaines D’Expertise





Mr. Rosie’s client representations include:

Mergers and Acquisitions

  • Abide Therapeutics in its sale to Lundbeck
  • Helio Vision in its sale to Aldeyra Therapeutics
  • iRobot Corporation in its acquisition of Robopolis SAS
  • LoJack Corporation in its $135 million sale to CalAmp Corp.
  • Mitralign in its sale to Edwards Lifesciences Corporation

Private Financings

  • Allurion Technologies in its $27 million Series C financing
  • ClimaCell in its Series B financing
  • Imagen Technologies in its preferred stock financings
  • PatientPing in its $31 million Series B financing
  • Vividion Therapeutics in its $50 million Series A financing

Public Offerings

  • argenx SE in its $115 million initial U.S. public offering
  • BeiGene, Ltd. in its $200 million, $201 million and $800 million follow-on public offerings
  • Proteostasis Therapeutics, Inc. in its $40 million follow-on public offering
Professional Activities

Mr. Rosie is a member of the Boston Bar Association. He holds office hours at the Harvard Innovation Lab and he has served as a mentor for the MIT $100K Entrepreneurship Competition.

Professional Experience

Mr. Rosie rejoined Goodwin in 2018 after serving as a senior corporate counsel at Pegasystems, where he worked on SEC compliance, mergers and acquisitions, and its corporate venture program. Prior to joining the firm, Mr. Rosie served as a senior corporate counsel at athenahealth, where he advised on corporate governance and securities matters, mergers and acquisitions, and the launch of athenahealth’s More Disruption Please innovation and partnership program.






J.D., 2011
New England School of Law
B.A., 2007
Stonehill College



Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique